Vladonix
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
A bovine thymus-derived peptide marketed to restore immune competence and slow age-related thymic decline. The case rests mostly on mechanism and animal data; human evidence is low-confidence, and claims of post-chemo recovery or lower mortality with long-term use are speculative. Chief risk is immune overstimulation in autoimmune conditions, plus low risks of allergy and prion exposure. Not FDA-approved; sold mainly as unregulated products online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Vladonix is a natural peptide bioregulator derived from the thymus gland of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and is the natural counterpart to Crystagen (the synthetic thymus peptide). Vladonix targets the thymus gland, where it is designed to normalize thymus function, stimulate and repair immunological activity, and support the immune system during aging.
The thymus is central to T-cell maturation and immune regulation, but undergoes progressive involution with age, shrinking significantly by middle age and contributing to the immunosenescence that makes older adults more susceptible to infections, cancer, and autoimmune conditions. Vladonix is positioned as a targeted approach to reversing or slowing this decline by providing thymus-specific peptides that interact with DNA to regulate gene expression and protein synthesis in thymic tissue.
Khavinson's research group reports that Vladonix has been shown to help restore patients' immunology after radiation and chemotherapy treatment, as well as after infectious diseases. The broader thymus peptide research (Thymalin, Thymogen) provides a more extensive evidence base from which Vladonix benefits are extrapolated.
How it works in the body
A bioregulator peptide complex derived from thymus gland tissue. It penetrates thymocyte nuclei to regulate gene expression involved in T cell maturation, thymic peptide secretion, and immune competence, counteracting age-related thymic involution.
Research overview
Vladonix benefits from the extensive research on thymus peptides, particularly Thymalin, a separate injectable thymus-extract medicine. The PMC-indexed review (PMC8365293) describes thymalin's use for immunocorrection in viral/bacterial infections, post-radiation states, and immunodepression, with molecular mechanism analysis of its component peptides. The landmark Kiev longevity study used Thymalin + Epithalamin in elderly patients over 6-12 years and showed significantly reduced mortality. Vladonix is a separate oral Cytomaxes thymus-peptide supplement, not an established oral equivalent of Thymalin. The broader peptide bioregulator theory holds that organ-specific short-chain peptides act as gene switches that can extend lifespan 20-40% in animal models. Direct clinical studies on Vladonix capsules specifically are limited to Khavinson Institute reports.
Who researches Vladonix?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(3)
Rated by level of concern
Allergic reaction to bovine thymus-derived peptides
LowClass inference from bovine-tissue extract preparations; no product-specific PubMed case reports located
Potential immune overstimulation in autoimmune conditions
ModerateMechanistic; PMID 9637345
Prion/BSE concerns (bovine thymus origin)
LowWHO/EU specified-risk-material classifications for bovine tissues; no reported TSE transmission from thymic peptide products
Interaction summary(8)
Rated by direction with this peptide
Immunosuppressants for transplant (tacrolimus, cyclosporine, mycophenolate, sirolimus)
CautionModerateA stated T-cell-stimulating agent works directly against the therapeutic goal of graft immunosuppression and could in principle contribute to rejection risk, so transplant recipients should not use it without their transplant team's knowledge.
Mechanistic (opposing pharmacodynamics); no interaction study exists - PMID 9637345 for the immunostimulant mechanism
Biologic and conventional DMARDs in autoimmune disease (TNF inhibitors, methotrexate, rituximab)
CautionTheoreticalAdding a thymic immunostimulant to a regimen deliberately dampening autoreactive T cells is pharmacodynamically opposed and has never been studied in autoimmune patients.
Mechanistic; no published clinical data
Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)
CautionTheoreticalBoth agents push in the same direction on T-cell activation, so a theoretical additive risk of immune-related adverse events exists, with no trial data on combining thymic peptide extracts with checkpoint blockade.
Mechanistic; no published combination data
Systemic corticosteroids
NeutralTheoreticalCorticosteroids are thymolytic and lymphopenic, so they would be expected to blunt or cancel any thymic-maturation effect - a pharmacodynamic antagonism rather than a safety hazard.
Mechanistic (glucocorticoid thymocyte apoptosis); no interaction study
Cytotoxic chemotherapy
ProtectiveTheoreticalThe proposed benefit is faster lymphoid recovery after myelosuppressive therapy, but the only supporting primary source used a different Khavinson peptide (Vilon) in elderly colorectal cancer patients and reported only preliminary, uncontrolled outcomes.
PMID 16075684
Vaccines (influenza, pneumococcal, COVID-19) in older adults
SynergisticTheoreticalA genuine thymic-output boost would plausibly improve vaccine responsiveness in immunosenescent adults, but no study has measured antibody titers or seroconversion with Vladonix or Thymalin as an adjuvant.
Mechanistic; no immunogenicity data located
Anticoagulants and antiplatelet agents
CautionTheoreticalA Thymalin COVID-19 report described accelerated decline in D-dimer and IL-6 alongside standard care, raising a speculative additive question about coagulation parameters, though no bleeding events or coagulation interaction have been reported.
PMID 33575961
Other Khavinson peptide bioregulators (e.g. Epithalamin/Epitalon)
SynergisticLowThe originating group's own long-term elderly cohort reported larger claimed mortality reduction from combined thymus plus pineal peptides than from either alone, but this comes from a single unreplicated, non-blinded source.
PMID 14523363
Known risks(3)
Allergic reaction to bovine thymus-derived peptides
LowNo serious adverse events reported in available literature.
Potential immune overstimulation in autoimmune conditions
ModerateThymus-targeting peptides modulate immune function. Individuals with active autoimmune conditions should consult a physician before use.
Prion/BSE concerns (bovine thymus origin)
TheoreticalManufacturers report use of certified BSE-free source animals.
Drug interactions(3)
Immunosuppressants (cyclosporine, tacrolimus, etc.)
Theoretical antagonism; immune-stimulating effects may counteract immunosuppression
Biologics for autoimmune conditions (TNF inhibitors, etc.)
Theoretical interaction; immune modulation may interfere with biologic therapy
Chemotherapy agents
Used sequentially in Russian practice for post-chemo immune recovery; timing important
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence (with stronger data for related injectable Thymalin)
- Total Studies
- 8
- Human Studies
- 200
Direct evidence for Vladonix capsules is limited to Khavinson Institute reports. However, the related injectable Thymalin has decades of Russian clinical use and the most extensive published data of any Khavinson peptide, including the landmark Kiev study showing mortality reduction over 6-12 years. The PMC-indexed thymalin review (PMC8365293) provides robust molecular mechanism data. Vladonix oral capsules are extrapolated from this stronger evidence base.
Researched for(4)
Rated by confidence in the evidence
Immune system restoration and normalization
LowBased mainly on injectable Thymalin data, not oral Vladonix, with unblinded, preliminary human reporting.
PMID 9637345; PMID 33237528; PMID 33575961
Post-radiation/chemotherapy immune recovery
SpeculativeIndirect evidence from a Vilon colorectal-cancer report indexed as a controlled clinical trial; it does not establish benefit for oral Vladonix.
PMID 16075684
Reduced mortality in long-term anti-aging protocols
SpeculativeBased on one unreplicated study of injectable peptides, not modern trial design or oral Vladonix.
PMID 14523363; PMID 12577695
Support against age-related immunosenescence
SpeculativeMechanism-based only, with no controlled study measuring immune aging markers before and after use.
PMID 9637345; PMID 33237528; PMID 25826983
Benefits(4)
Immune system restoration and normalization
Thymalin research program; PMC8365293; Khavinson Institute reports
Post-radiation/chemotherapy immune recovery
Thymalin clinical literature; Vladonix product clinical reports
Mortality reduction has been reported with Thymalin and Epithalamin; it has not been established for oral Vladonix.
Kiev longevity study (Thymalin + Epithalamin, 6-12 year follow-up)
Support against age-related immunosenescence
Khavinson bioregulator research program; thymus involution reversal data
Key studies(2)
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
ReviewN/A (review)Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM
Biology Bulletin Reviews
2021
Comprehensive review of thymalin and component peptides. Thymalin shows immunocorrective activity in viral/bacterial infections, post-radiation/chemo states, and immunodeficiency. Component peptides regulate gene expression, cytokines, heat-shock proteins, and cell differentiation.
Anisimov VN, Khavinson VKh
Biogerontology
2010
Long-term application of peptide bioregulators in humans led to significant rehabilitation of physiological functions and reliable mortality decrease in different age groups over 6-12 years.
Regulation & availability
Why researchers look at it
Vladonix targets the thymus gland -- the master organ of immune function -- with peptides aimed at reversing age-related immune decline. It draws on the most extensive evidence base of any Khavinson bioregulator through the related injectable Thymalin.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not named in the 2026 List. This does not establish permission or prove that WADA has never evaluated it. Assess the product's ingredients against S0 and other prohibited categories.
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Not available through conventional pharmacies in USA/EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(4)
- 1970s-1980sThymalin, a separate injectable thymus-extract medicine, was developed; its clinical history does not establish efficacy of oral Vladonix.
- 2000sVladonix (oral Cytomaxes form) developed and commercialized in Russia
- 2010sgrowing Western awareness
- 2021PMC-indexed thymalin review published (PMC8365293)
Sources & FAQs
Research sources(2)
Frequently asked questions(3)
What is the difference between Vladonix and Thymalin?
Thymalin is an injectable polypeptide preparation with decades of clinical use in Russian hospitals. Vladonix is a separate oral thymus-peptide supplement in the Cytomaxes range. It is not established as an orally equivalent formulation of Thymalin. Both target the thymus but differ in route of administration and clinical evidence base (Thymalin has more published data).
How does Vladonix compare to Crystagen?
Vladonix is a natural extract (Cytomaxes) from calf thymus tissue, while Crystagen is a synthetic peptide (Cytogens) synthesized from amino acids. Both target the immune system. Some practitioners use both, with Vladonix providing the full peptide complex and Crystagen providing specific synthetic peptide sequences.
Who should consider Vladonix?
In Russian practice, Vladonix is recommended for age-related immune decline, recovery from infections, post-radiation/chemotherapy immune support, and as part of general anti-aging protocols.